Midostaurin

133 interactions 1 explained in plain English 326 cited references

Also sold as: Rydapt Rydapt®

About Midostaurin

Midostaurin is used with other chemotherapy drugs to treat certain types of acute myeloid leukemia (AML; a type of cancer of the white blood cells). Midostaurin is also used to certain types of mastocytosis (a blood disorder in which there are too many mast cells [a certain kind of white blood cell]). Midostaurin is in… Read the full Midostaurin drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Bacillus Of Calmette And Guerin Vaccine, Live Measles Virus Vaccine, Live Dengue Tetravalent Vaccine, Live Mifepristone Mumps Virus Vaccine, Live Ensitrelvir

11 Contraindicated 116 Major 6 Moderate

All (133) Contraindicated (11) Major (116) Moderate (6)

Contraindicated

Midostaurin Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Midostaurin Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details Midostaurin Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Midostaurin Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Midostaurin Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Midostaurin Relugolix Orgovyx Increased relugolix exposure Details Midostaurin Simvastatin Flolipid Increased OATP1B1 substrate exposure Details Midostaurin Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Midostaurin Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Midostaurin Atorvastatin Atorvaliq Increased OATP1B1 substrate exposure Details Midostaurin Digoxin Cardoxin® Increased digoxin exposure Details Midostaurin Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Midostaurin Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Irinotecan Camptosar Increased BCRP substrate exposure Details Midostaurin Irinotecan Injection Camptosar Increased BCRP substrate exposure Details Midostaurin Ketoconazole Topical Extina® Foam Increased midostaurin exposure Details Midostaurin Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Midostaurin Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Midostaurin Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Midostaurin Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Midostaurin Letermovir Injection Prevymis Increased OATP1B1 substrate exposure Details Midostaurin Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Midostaurin Methotrexate Jylamvo Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Methotrexate Injection Abitrexate® Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Adagrasib Krazati Increased CYP3A4 substrate exposure Details Midostaurin Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Midostaurin Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Midostaurin Apalutamide Erleada Decreased midostaurin exposure Details Midostaurin Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Midostaurin Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Midostaurin Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Midostaurin Boceprevir Increased midostaurin exposure Details Midostaurin Bosentan Increased OATP1B1 substrate exposure Details Midostaurin Bupropion Aplenzin Decreased CYP2B6-substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.